These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29636547)

  • 1. BRD4 facilitates replication stress-induced DNA damage response.
    Zhang J; Dulak AM; Hattersley MM; Willis BS; Nikkilä J; Wang A; Lau A; Reimer C; Zinda M; Fawell SE; Mills GB; Chen H
    Oncogene; 2018 Jul; 37(28):3763-3777. PubMed ID: 29636547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
    Rhyasen GW; Yao Y; Zhang J; Dulak A; Castriotta L; Jacques K; Zhao W; Gharahdaghi F; Hattersley MM; Lyne PD; Clark E; Zinda M; Fawell SE; Mills GB; Chen H
    PLoS One; 2018; 13(7):e0200826. PubMed ID: 30036377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo.
    Xu K; Chen D; Qian D; Zhang S; Zhang Y; Guo S; Ma Z; Wang S
    Biochem Biophys Res Commun; 2018 May; 499(3):531-537. PubMed ID: 29596834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo.
    Shen G; Chen J; Zhou Y; Wang Z; Ma Z; Xu C; Jiang M
    Cell Physiol Biochem; 2018; 50(2):798-809. PubMed ID: 30308485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
    Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
    Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.
    Yeh TC; O'Connor G; Petteruti P; Dulak A; Hattersley M; Barrett JC; Chen H
    Clin Cancer Res; 2017 Feb; 23(4):1025-1035. PubMed ID: 28073847
    [No Abstract]   [Full Text] [Related]  

  • 15. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
    Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
    Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage.
    Lam FC; Kong YW; Huang Q; Vu Han TL; Maffa AD; Kasper EM; Yaffe MB
    Nat Commun; 2020 Aug; 11(1):4083. PubMed ID: 32796829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
    Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
    Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
    Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
    Front Immunol; 2020; 11():89. PubMed ID: 32184777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.